Please ensure Javascript is enabled for purposes of website accessibility

Be Careful What You Wish For

By Brian Orelli, PhD - Updated Apr 6, 2017 at 1:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Do you have the stomach to profit from swine flu?

Novartis (NYSE:NVS) investors are in a bit of a conundrum. There's potential for the company to make some extra revenue, but investors are going to have to hope that the swine flu pandemic gets worse.

A few weeks ago, Novartis, sanofi-aventis (NYSE:SNY), and GlaxoSmithKline (NYSE:GSK) were awarded contracts to produce vaccines for the U.S., and it looks like Novartis is well on its way to fulfilling its contract. The company said today that it's made enough of the viral particles needed for a vaccine to start preclinical tests. It further expects to get a vaccine into clinical trials next month, which would put it in shape to have vaccine ready for the fall flu season.

Novartis was able to get the vaccine program up and running so quickly because it's using cell culture to make it, instead of the more traditional chicken eggs, which have to incubate longer in the laboratory, so to speak. Both Baxter (NYSE:BAX) and Novavax also have technology to make vaccines that are produced in cell culture.

The World Health Organization said the flu outbreak had become a pandemic yesterday, but it's important to remember that pandemic is defined by the spread of the virus, not by its severity. And how brutal the virus is will ultimately determine how well vaccine makers will prosper during the pandemic, along with companies that sell antiviral medications like Roche and Gilead Sciences' (NASDAQ:GILD) Tamiflu.

And that's ultimately the problem with investing in the hopes of making money off the swine flu. Trying to figure out whether people will buy Apple's (NASDAQ:AAPL) new iPhone or eat at Chipotle Mexican Grill (NYSE:CMG) can be as easy as asking your friends and family what they think. Asking a virus whether it's going to mutate into a killing machine so investors can make money is a bit harder.

A pandemic of Foolishness awaits you:

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novartis AG Stock Quote
Novartis AG
NVS
$87.92 (0.12%) $0.11
Apple Inc. Stock Quote
Apple Inc.
AAPL
$149.24 (2.54%) $3.70
Sanofi Stock Quote
Sanofi
SNY
$52.90 (0.65%) $0.34
Chipotle Mexican Grill, Inc. Stock Quote
Chipotle Mexican Grill, Inc.
CMG
$1,322.06 (1.77%) $22.99
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.18 (1.51%) $0.94
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$44.71 (0.77%) $0.34
Baxter International Inc. Stock Quote
Baxter International Inc.
BAX
$74.34 (0.88%) $0.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.